Melanoma Research Alliance Appoints Stephanie Kauffman as Chief Executive OfficerWASHINGTON, June 04, 2026 (GLOBE NEWSWIRE) -- The Melanoma Research Alliance (MRA), the world's leading nonprofit funder of melanoma research, today announced the appointment of Stephanie Kauffman as Chief Executive Officer, effective July 1, 2026. Kauffman succeeds Marc Hurlbert, PhD, who will depart MRA after eight years of leadership to become Chief Executive Officer of the National Kidney Foundation.
Leveraged Finance & Private Equity Communities Unite to Raise Record $3 Million for Melanoma Research
On Thursday, June 16, 2022, more than 900 people from over 100 firms from the leveraged finance and private equity communities came together for the Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party. Hosted at the Museum of Modern Art, the event raised a record breaking $3 million for the Melanoma Research Alliance’s (MRA) mission to advance the world’s most innovative and promising melanoma research.
Melanoma Research Alliance Announces $13 Million in Grants to Advance Melanoma Prevention, Detection & Treatment
Coinciding with Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 27 research grants totaling $13,046,774 to support new research aimed at advancing melanoma prevention, diagnosis and treatment. Melanoma is the deadliest form of skin cancer and the fifth most common cancer in the United States.
The Melanoma Research Alliance Names Dr. Marc Hurlbert as Chief Executive Officer
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced that its Board of Directors appointed Marc Hurlbert, PhD, as its new Chief Executive Officer.
Melanoma Research Alliance Statement on FDA Approval of Relatlimab + Nivolumab for Treatment of Advanced Melanoma
The Melanoma Research Alliance (MRA) released the following statements from MRA’s Chief Science Officer Marc Hurlbert, PhD and President & CEO Michael Kaplan on the Food & Drug Administration approval of relatlimab plus nivolumab:
Melanoma Research Alliance Statement on FDA Approval of Tebentafusp, the First Drug for Treating Metastatic Uveal Melanoma
The Melanoma Research Alliance (MRA) released the following statements from MRA Chief Science Officer Marc Hurlbert, PhD and MRA President & CEO Michael Kaplan on the Food & Drug Administration approval of tebentafusp, the first drug for treating metastatic uveal melanoma:
Melanoma Research Alliance Applauds Expanded Approval of Pembrolizumab to Patients with Stage 2 Disease
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Merck’s Keytruda (pembrolizumab) to include patients with Stage IIB and IIC melanoma.
Leveraged Finance & Private Equity Communities Come Together to Raise $2.4 Million at 10th Annual Leveraged Finance Fights Melanoma Event
More than 750 people representing more than 80 firms from across the leveraged finance and private equity communities came together at the Museum of Modern Art for the 10th annual Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party. The event raised more than $2.4 million for the Melanoma Research Alliance (MRA) lifesaving research program.
Melanoma Research Alliance Announces 13 Dermatology Fellowship Award Recipients
The Melanoma Research Alliance, the largest non-profit funder of melanoma research, is proud to announce its 2021 Dermatology Fellowship Award recipients.
Melanoma Research Alliance Announces $8.1 million in Research Awards
The Melanoma Research Alliance, the largest non-profit funder of melanoma research, is proud to announce $8.1 million in funding for 34 new research awards. The awards, issued near the start of Melanoma Awareness Month, provide critical funding to address urgent unmet needs in melanoma.
